The IPO window for surgical robotics is slowly reopening, but companies must show strong procedure rates, utilization, and a clear path to profitability to attract institutional investors.
Leaders from Noah Medical, Distalmotion, and Neocis shared their commercialization progress, competitive positioning, and capital strategies in a cautious fundraising climate still dominated by Intuitive Surgical.
Medtech investors today demand not just innovation but sustainable growth, with many expecting 25%+ revenue growth and proof that newer players can scale profitably in a maturing robotics market.

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

More from Interviews